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Abstract p73, a transcription factor of the p53 family,
plays a key role in many biological processes including
neuronal development. Indeed, mice deficient for both
TAp73 and ΔNp73 isoforms display neuronal pathologies,
including hydrocephalus and hippocampal dysgenesis, with
defects in the CA1-CA3 pyramidal cell layers and the
dentate gyrus. TAp73 expression increases in parallel with
neuronal differentiation and its ectopic expression induces
neurite outgrowth and expression of neuronal markers in
neuroblastoma cell lines and neural stem cells, suggesting
that it has a pro-differentiation role. In contrast, ΔNp73
shows a survival function in mature cortical neurons as
selective ΔNp73 null mice have reduced cortical thickness.
Recent evidence has also suggested that p73 isoforms are
deregulated in neurodegenerative pathologies such as
Alzheimer’s disease, with abnormal tau phosphorylation.
Thus, in addition to its increasingly accepted contribution
to tumorigenesis, the p73 subfamily also plays a role in
neuronal development and neurodegeneration.
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The Molecular Nature of p73
p73 is a member of the p53 family [1], although p73 (and
p63) are more closely related to the ancestral form of the
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DOI 10.1007/s12035-011-8172-6protein than p53. These three mammalian genes encode
transcription factors that play key roles as regulators of
proliferation, differentiation, cell death, stem cell renewal,
and cell fate commitment [2–4]. All p53 family genes
contain the same modular domain structure, including an
amino-terminal transactivation domain (TA), a DNA-
binding domain and a carboxy-terminal oligomerization
domain. The p73 gene contains 15 exons and transcription
can be initiated from two N-terminal promoters (Fig. 1).
Transcription from the most upstream ATG (promoter 1)
generates the transactivating (TA) isoforms, while the
second promoter, situated within intron 3, yields amino-
terminal truncated proteins (ΔN isoforms). In general,
TA and ΔN isoforms display distinct biological activi-
ties. The TA isoforms induce cell cycle arrest and
apoptosis, and are therefore candidate tumour suppressors
[5, 6]w h i l et h et r u n c a t e dΔN isoforms are (generally)
pro-survival and favour oncogenic transformation [7]. In
addition, both TAp73 and ΔNp73 transcripts undergo
alternative C-terminal splicing, generating, in theory, up to
seven different variants of each in normal cells, although not
all these have been detected at the protein level [8–10]. This
complexity has led to significant difficulties in understanding
the biology of p73.
It is, however, now generally accepted that ΔN isoforms
largely act as dominant negative inhibitors of the activity of
TA isoforms, both by competing for consensus elements in
promoter DNA and by dimerisation [7, 11]. However, this
generalisation must be qualified since the longest ΔNp73α
isoform contains a second C-terminal TA domain and can
transactivate a set of genes distinct from that recognised by
TAp73. Moreover, the α isoforms of both TA and ΔNp73
contain a C-terminal transactivation inhibitory domain,
which can compromise the transcriptional activity mediated
by the N-terminal TA domain as a result of intramolecular
interactions. Thus, to regard the output of p73 expression as
the resultant of the ratio between TA and ΔN isoform
expression may be an oversimplification.
The Biology of p73: Lessons from Transgenic Mice
The human Trp73 gene was identified in 1997 when it was
localised within chromosome 1p36, a region frequently
deleted in tumours such as neuroblastoma and other late-
stage human cancers [12, 13]. Monosomy 1p36 is also
associated with developmental brain abnormalities [14].
Although genes other than p73 within the 1p36 region, such
as CHD5, may also contribute to these phenotypes, these
data suggest that p73 may have a role in neural develop-
ment as well as in cancer.
This developmental role for p73 is substantiated by the
phenotype of total p73 knockout mice. Unlike the tumour-
susceptible p53 null mice, total p73 knockout mice do not
develop tumours but show developmental defects in the
central nervous system (Table 1)[ 15], including congenital
hydrocephalus and hippocampal dysgenesis, with abnor-
malities in the CA1–CA3 pyramidal cell layers and the
dentate gyrus. In keeping with these anatomical abnormal-
ities, the total p73
−/− knockout mice also have defects in
both embryonal and adult neurogenesis, suggesting that p73
isoforms may be survival factors for neural stem cells [16].
p73
−/− mice also have a reduction in cortical thickness as a
consequence of loss of mature cortical neurons [17].
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Fig. 1 p73 gene structure.
a Genomic organisation of p73
and representation of different
splicing variants that give rise to
the isoforms of p73. The P1
promoter generates the TA
isoforms, while the P2 promoter
produces the ΔN isoforms.
b Schematic representation of
the domains encoded by the
different isoforms of p73. On
top, there are indicated the
aminoacids included in each
domain. TA transactivation
domain, DBD DNA-binding
domain, OD oligomerization
domain, SAM SAM domain,
TID transactivation inhibitory
domain
140 Mol Neurobiol (2011) 43:139–146This neurological phenotype has been attributed primarily
to the loss of ΔNp73 isoforms, since these are expressed in
post-mitotic neurons and act as survival factors [11]. Thus,
NGF withdrawal or overexpression of p53 in sympathetic
cervical ganglion cells leads to a reduction of endogenous
ΔNp73 levels and apoptosis which is prevented by over-
expression of ΔNp73 [18]. Recently, the generation of
ΔNp73 isoform-specific KO mice has confirmed the
prosurvival role of ΔNp73 in differentiated mature neurons
[19]. Indeed, neuronal density in the motor cortex of
ΔNp73
−/− mice is significantly reduced after 10 months of
age and progresses with evidence of neurodegeneration [20],
although there were no striking hippocampal abnormalities.
The same phenotype is also evident in a second ΔNp73
−/−
mouse model [21]. In particular, it has been observed that the
number of vomeronasal neurons and Cajal-Rezius cells was
profoundly reduced, and that the choroid plexuses were
atrophic.
However, the severity of the neurological defects observed
intheΔNp73-specificknockoutisnotasdramaticasthatseen
in the total p73
−/− mice, suggesting that TAp73 may also
contribute to the development of the CNS. While cortical
thickness in selective TAp73 null mice is normal, they show
hippocampal dysgenesis with loss of the lower blade of the
dentate gyrus similar to that seen in total p73
−/− mice at P14,
before the complicating effect of ventricular enlargement
further distorts the hippocampal architecture in the total
knockout [22]. This anatomical phenotype is reflected in the
reduction in neurogenesis in the subgranular zone of the
dentate gyrus (Fig. 2), suggesting that TAp73 may be
required for neural stem cell proliferation [23]. Indeed,
TAp73 has been shown to regulate the negative bHLH Hey2
which is known to sustain maintenance of neural precursors.
Thus, the isoform-selective knockout studies suggest that
TAp73 and ΔNp73 contribute to CNS development in ways
that are only partially overlapping.
Differentiation or Stemness?
Both embryonic and adult neural stem cells (NSC) are
primary precursors that have the ability to differentiate into
different cell types (neurons, astrocytes and oligodendro-
cytes) while retaining the capacity to produce identical
NSC progeny (self-renewal) [24], and p53 and ΔNp63
have already been implicated in NSC biology [25, 26].
Recently, four independent groups [16, 23, 27, 28] have
demonstrated that p73 is also a positive regulator of
embryonic and adult NSC and some of this in vivo
evidence has been discussed above.
NSC can be cultured in vitro as neurospheres and
subsequently differentiated into mature neurons. Neuro-
spheres derived from p73
−/− mice are smaller, with a
reduced number of cells in S phase and an increase in the
Table 1 Neuronal defects in p73 transgenic mice
p73
−/−
(Yang et al. [15], Pozniak et al. [17])
TAp73
−/−
(Tomasini et al. [22])
DNp73
−/−
(Wilhelm et al. [19])
Anatomical defect
Cortex Hypoplasia None Age-dependence hypocellularity
and cortex thinning
Hippocampus Dysgenesis Absence lower blade of
dentate gyrus
None
Ventricular Third ventricle enlarged and hydrocephalus None Enlarged ventricle
Others Loss of Cajal-Retzius neurons and Reelin defective.
Abnormalities of the pheromone sensory pathway
Behavioural test (Talos et al. [16], Wetzel et al. [19]) (Personal communication) (Personal communication)
Young Aged Young Aged Young Aged
Burrowing NT NT Reduced Reduced NT Normal
Clasping Positive Reduced
a Positive Positive NT Positive
Open field Reduced Reduced
a Reduced Reduced NT Reduced
Barnes Maze Reduced Reduced
a NT NT NT NT
Hind grip Loose Reduced
a NT NT NT NT
Light–dark box Positive NT NT NT NT NT
Young mice: 2–4 months old. Aged mice: 15–17 months old
NT not tested
aThe behavioural experiments were performed in p73
+/− mice
Mol Neurobiol (2011) 43:139–146 141senescent population [16]. At the molecular level, it has
been shown that NSC from p73
−/− mice have transcriptional
dysregulation of Sox-2, Sox-3, Nanog, Notch-I, Notch-2,
Hes-5, Jag2 and Deltex, which are all components of
signalling pathways involved in the regulation of prolifer-
ation and/or self-renewal [29], although further studies are
required to address how p73 physiologically regulates these
factors. TAp73 is the predominant isoform expressed in
embryonic NSC, and endogenous expression of TAp73
increases during differentiation of NSC [27]. Further
studies have shown that smaller numbers of neurons can
be derived from p73
−/− NSC which do not fully differen-
tiate, with defects in arborization of the dendritic tree and in
physical connectivity. This is reflected in the anatomy of
hippocampal neurons in the dentate gyrus of p73
−/− mice in
vivo, which show a reduced number of branches when
compared to normal mice (Fig. 3).
p73 has also been implicated in oligodendrocyte as well
as neuronal differentiation [30], and oligodendrocytic
differentiation from p73
−/− NSC is also impaired, with
lower numbers and poorer quality than those derived from
wild type NSC. However, dissociated p73
−/− NSC retain the
ability to differentiate into neurons, astrocytes and oligo-
dendrocytes, indicating that loss of p73 does not affect the
multipotency of NSC.
Another, though perhaps less definitive model implicat-
ing p73 in neurogenesis is the terminal differentiation of
neuroblastoma cells induced by retinoic acid (RA) and
which is associated with an increased expression of TAp73.
In addition, ectopic expression of TAp73 itself induces
terminal neuronal differentiation. During RA treatment,
TAp73 isoforms regulate the N-CAM promoter, while
ectopic expression of TAp73 led to a down-regulation of
N-MYC and an increased expression of pRB, mimicking
the RA effect on these two genes [31], which are crucial for
neuroblastoma survival [32, 33].
In conclusion, while recent work indicates a clear
requirement for p73, and particularly TAp73 in the
maintenance of stemness via a yet not fully identified
mechanism both in vivo and in vitro [16, 23, 27, 28],
other data suggest an involvement of p73 in neuronal [31]
and oligodendrocyte [30] differentiation. These multiple
biological activities in the nervous system may reflect the
p73+/+ p73-/-
Fig. 3 Hippocampal neuron morphology is altered in the dentate
gyrus of knockout (p73
−/−) mice. Golgi staining of dentate gyrus from
normal (p73
+/+) and p73
−/− mice (age=18 days after birth). Knockout
mice show reduced branching and connectivity of neurons. A
representative photomicrograph is shown. Scale bars 100 μm( top
panel) and 50 μm( low panel)
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Fig. 2 Reduction of the
putative stem cell in the dentate
gyrus from p73
−/− mice. The
dentate gyrus from day 7 after
birth (P7) of normal (p73
+/+)
and knockout (p73
−/−) mice was
stained with antibodies to glial
fibrillary acidic protein (GFAP)
and nestin. Arrows indicate
double-positive cells. Knockout
mice show nearly half of
GFAP/Nestin cells, indicating a
very reduced stemness potential
in these mice. GL granular cell
layer, ML molecular cell layer,
Hil hilus. Scale bars 50 μm
142 Mol Neurobiol (2011) 43:139–146molecular complexity of the 14 protein isoforms of p73,
their interactions with each other as well as their interplay
with other p53/p63 family members, which are them-
selves expressed as multiple isoforms. Alternatively,
since p73 appears to regulate between 1,000 and 2,000
genes, including 100–200 transcription factors, several
apparently divergent pathways could be simultaneously
activated.
p73 and Neurodegeneration
During the last 15 years, it has emerged that the p53 family
has an important role in several neurodegenerative diseases.
Of special interest to us, and on which we will focus, is
their role in the most (and increasingly) prevalent form of
neurodegeneration, Alzheimer’s disease (AD).
AD exists as both familial and sporadic forms. The
familial early onset (EOAD) form, accounting for only a
small percentage of cases, is inherited via mutations in
either the β-amyloid precursor protein (APP) or one of the
two presenilins (PS), PS1 and PS2. In contrast, the greatest
genetic risk for the sporadic, late onset (LOAD) form is the
ε4 allele of apolipoprotein E (APOE) [34]. Recently,
genome-wide association studies have identified three
additional risk genes, albeit with much weaker effects than
APOE; ApoJ/CLU, PICALM and CR1 [35, 36]
Both sporadic and familial forms of the disease are
characterised by two brain lesions: senile plaques—
extracellular deposits of the β-amyloid (Aβ)p e p t i d e ;
and neurofibrillary tangles (NFTs)—intracellular aggre-
gates of paired helical filaments (PHF) composed of
hyperphosphorylated forms of the microtubule associated
protein, tau [37]. The appearance of senile plaques
precedes that of NFTs. Aβ is derived by proteolytic
processing from the APP, with the presenilins being a
necessary component of the γ-secretase complex respon-
sible for the final stage of this process [37]. The
phosphorylation state of tau regulates its ability to bind
microtubules; in its hyperphosphorylated state tau is
unbound and eventually polymerises into paired helical
filaments, which then aggregate into NFTs. It is emerging
that it is not these insoluble aggregates of tau, but rather
some soluble form that is the toxic species responsible for
neuronal dysfunction and eventually neuronal death [38].
That mutations in APP give rise to increased Aβ
production (as do mutations in the presenilins, as
subsequently observed), and as senile plaque appearance
precedes that of NFTs, the amyloid cascade hypothesis
was formulated [39]. This hypothesis, which has not yet
been refuted, holds that increased levels of Aβ lead to the
hyperphosphorylation of tau which then leads to neuronal
dysfunction and eventually neurodegeneration. Attempts
to model this cascade of events in mice has for the most
part failed, as even when mutant transgenic forms of both
APP and PS1 are introduced, despite high levels of Aβ
production leading to extensive plaque formation, the
aggregation of tau is not observed. It is only when APP,
PS1 and human tau are concomitantly over expressed in
triple transgenic mice that both plaques and tangles are
observed.
The first indication that the p53 family may play a
role in AD came in 1996 with the demonstration that
intracellular Aβ upregulates p53 in the brains of
transgenic mice overexpressing just the Aβ fragment of
APP [40]. That same year, the Kosik group examined
neurons from a p53
−/− mouse, observing that p53 has a
role in neuronal differentiation and in tau phosphorylation
[41]. In 2001 use of pifithrin-α, an inhibitor of p53-
dependent gene transcription was shown to protect
neurons against Aβ-induced apoptosis [42]. The p53
protein was also found to be upregulated in the brain of
AD sufferers [43] ,af i n d i n gw h i c hw el a t e rc o n f i r m e d
[44]. In 2004, Caricasole et al. [45] showed that Aβ
activates the expression of the p53 target gene encoding
the soluble wnt antagonist, Dickkopf-1 (Dkk1) [46], and
that knock-down of Dkk1 in primary neurons almost
completely blocked Aβ-induced tau phosphorylation,
implicating the p53 family in the “amyloid cascade”
pathway. In the same year, it was also reported [47]t h a t
the p73 protein exhibits an altered subcellular distribution
in AD brain. In hippocampal pyramidal neurons of control
subjects, p73 immunoreactivity was predominately cyto-
plasmic, while in AD samples increased levels of p73
were found in the nuclei of pyramidal neurons and in
dystrophic neurites.
We employed a simple cell model to show that
transcriptionally active forms of p53 are able to induce
tau phosphorylation at specifc phosphoepitopes, particu-
larly the AT8/Tau-1 (S199, S202 and S205) and PHF-1
(S396 and S404) sites [44]. We found that this also holds
true for p73, with the TA forms increasing tau phosphor-
ylation, while the ΔN forms do not [48]. In this system, we
also found that transcriptionally active forms of p63
activate tau phosphorylation, while ΔNp63 forms do not
(unpublished observations).
In 2008, the Miller/Kaplan group [49] reported that in
brains of aged (16–18 months) heterozygous p73
+/− mice,
there were substantial increases in tau phosphorylation
levels together with filamentous aggregates of hyper-
phosphorylated tau with similarities to NFTs. When they
crossed these haploinsufficent p73 mice with mice
harbouring a double mutant form of APP (the TgCRND8
mouse), tau phosphorylation and tau filament formation
occurred as early as 1.5 months. This finding is especially
remarkable given that Aβ-based mouse models of AD do
Mol Neurobiol (2011) 43:139–146 143not manifest overt tau pathology. It also lends yet further
support to the amyloid cascade hypothesis, showing that
Aβ lies upstream of tau pathology and also that the
cascade of events that Aβ must set into motion, leading to
the hyperphosphorylation of tau and subsequent neuro-
degeneration, involves the p53 family, and in particular
p73.
The Miller/Kaplan group went on to show [49]t h a ti n
primary cortical neurons generated from p73 KO mice the
activity of c-jun N-terminal kinase (JNK) increased as the
number of WT p73 alleles decreased, and that JNK
inhibition decreased tau phosphorylation in these neurons.
They propose that, since ΔNp73 can bind and inhibit JNK,
which the TA forms of p73 cannot, it is the loss of the ΔN
forms of p73 that brings about tau phosphorylation and
neurodegeneration. The same group has previously demon-
strated that ΔNp73 plays a neuroprotective role in the CNS
[17, 50] and also claim that ΔN forms of p73 predominate, at
least in the postnatal mouse brain. The loss of one copy of
the entire p73 gene results in a reduction in ΔNp73 isoforms
leading to an increase in JNK activity.
In support of this claim, there is an extensive literature
implicating JNK in AD pathology, e.g. [51–53]. Our group
has shown that JNK directly targets tau [54] and also plays
a role in the regulation of APP processing [55]. Inhibiting
JNK has also been shown to protect against Aβ toxicity in
an APP/PS1 brain slice model of AD [56].
There exists one other knock-out mouse with a pheno-
type that includes neurodegeneration with accompanying
aggregates of hyperphosphorylated tau filaments [57]. The
deleted gene is Prolylisomerase-1, which is associated with
Aβ production and aggregation through its binding with
phospho-Thr688 of APP, and tau phosphorylation through
interaction with phospho-Thr231 of tau. Of interest, Pin1
also stabilises TAp73 via the c-Abl pathway [58].
Aβ has been shown to activate c-Abl and increase
p73 levels [59], while the Swedish mutant form of APP
increases expression from both the TA and ΔN promoters
of the p73 gene, but results in an overall increase in the
TA forms [60]. It appears then that p73 plays a key role in
AD and, in particular, that the balance between the TA and
ΔN forms is crucial. However, from the above, and other
observations such as the fact that p53 transcriptional
activity is regulated by the presenilins and that many of
the components of the γ-secretase complex are themselves
r e g u l a t e db yp 5 3[ 61], it would seem unlikely that p73
acts alone. Further investigations into p73 interactions
with other p53 family members, in particular p53 itself,
within nervous tissues will undoubtedly aid our under-
standing of its roles in both normal adult brain and in the
pathogenic processes underlying Alzheimer’sd i s e a s e .
Conclusion
From these studies, it emerges that p73 is the p53 family
member with a fundamental role in central nervous
system development and maintenance, and even in its
degeneration. Indeed, as shown in Fig. 4, the p73 gene
plays a role throughout the neurogenesis process, from
neural stem cells to mature postmitotic neurons. Although
perhaps simplistic at this stage, these new findings suggest
that TAp73 is the isoform essential for neuronal differen-
tiation and maintenance of neural stem cells. In contrast,
ΔNp73 seems to play a major role in neuronal survival.
However, the phenotype observed in isoform specific
knock-out mice is milder than that in the full knock-out
mice, indicating that, as in cancer, it is the interaction
between p73 isoforms, which ultimately determines the
phenotype.
Neurons
Oligodentrocytes
Astrocytes
Neural stem cells
TAp73
5, Jag2 and Deltex 
?
?
TAp73
Np73
Sox-2, Sox-3, Nanog, Notch-I, Notch-2  Hes-
Self-renewal
Fig. 4 Role of p73 in
neurogenesis. Functional
neurons are generated from
neural stem cells and then after
maturation, integrated in
neuronal circuits. TAp73 is
essential for neuronal
differentiation and maintenance
of neural stem cells. ΔNp73
plays a major role both as a
survival mechanism as well as
yet unknown pathways.
Question marks indicate that
molecular mechanism has not
been fully investigated yet
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